Serious infections associated with anticytokine therapies in the rheumatic diseases

Journal of Intensive Care Medicine

Volumn 19, Issue 6, 2004, Pages 320-334

  Giles, Jon T ^a   Bathon, Joan M ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Adalimumab; Bistoplasmosis; Etanercept; Infection; Infliximab; Rheumatoid arthritis; TNF; Tuberculosis

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA; ANTIRHEUMATIC AGENT; IL1RN PROTEIN, HUMAN; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MONOCLONAL ANTIBODY; SIALOGLYCOPROTEIN; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTIFICIAL VENTILATION; BRONCHOSCOPY; CASE REPORT; CROHN DISEASE; FEMALE; HISTOPLASMOSIS; HUMAN; LABORATORY TEST; LUNG LAVAGE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TUBERCULOSIS; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG APPROVAL; DRUG SCREENING; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HISTOPLASMA; IMMUNE DEFICIENCY; IMMUNOLOGY; MIDDLE AGED; POSTMARKETING SURVEILLANCE; UNITED STATES;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DRUG APPROVAL; DRUG EVALUATION, PRECLINICAL; FEMALE; HISTOPLASMA; HISTOPLASMOSIS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PRODUCT SURVEILLANCE, POSTMARKETING; RECEPTORS, TUMOR NECROSIS FACTOR; RHEUMATIC DISEASES; SIALOGLYCOPROTEINS; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 16644398295     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066604267854     Document Type: Review

References (104)

1. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344:907-916.
2. Firestein GS, Alvaro-Gracia JM, Maki R, Alvaro-Garcia JM. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol. 1990;144:3347-3353.
3. US Food and Drug Administration Arthritis Advisory Committee. Briefing information. March 4, 2003. Available at: http://www.fda.gov/ohrms/dockets/ac/ 03/briefing/3930b1.htm. Accessed August 2003.
4. Mohler KM, Torrance DS, Smith CA, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol. 1993;151:1548-1561.
5. US Food and Drug Administration Arthritis Advisory Committee. Briefing document for Enbrel (etanercept) for the treatment of ankylosing spondylitis. June 24, 2003. Available at: http://www.fda.gov/ohrms/dockets/ac/03/briefing/ 3967b2.htm. Accessed August 2003.
6. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine. 1995;7:251-259.
7. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549.
8. Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993;36:1681-1690.
9. Weinblalt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48:35-45.
10. Fleischmann RM, Schechtman J, Bennett R, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum. 2003;48:927-934.
11. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Eng J Med. 1996;334:1717-1725.
12. Fisher CJ, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med. 1996;334:1697-1702.
13. Fisher CJ, Dhainaut JFA, Opal SM, et al. Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome. JAMA. 1994;271:1836-1843.
14. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 1998;41:2196-2204.
15. Cohen S, Hurd E, Cush J, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46:614-624.
16. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994;344:1105-1110.
17. Maini R, St Clair EW, Breedveld F, et al. Infliximab chimeric anti-tumour necrosis factor alpha monoclonal antibody versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet. 1999;354:1932-1939.
18. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997;337:141-147.
19. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med. 1999;130:478-486.
20. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340:253-259.
21. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343:1586-1593.
22. Elliott MJ, Maini RN, Feldmann M, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet. 1994;344:1125-1127.
23. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41:1552-1563.
24. van de Putte LB, Atkins C, Malaise M,. Adalimumab (D2E7) monotherapy in the treatment of patients with severely active rheumatoid arthritis. Arthritis Rheum. 2002;46(suppl 9):S205.
25. Baum J. Infection in rheumatoid arthritis. Arthritis Rheum. 1971;14:135-137.
26. Rimoin DL, Wennberg JE. Acute septic arthritis complicating chronic rheumatoid arthritis. JAMA. 1966;196:617-621.
27. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46:2287-2293.
28. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002;46:2294-2300.
29. Dye C, Scheele S, Dolin P, Pathania V, Raviglione RC. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. JAMA. 1999;282:677-686.
30. Small PM, Fujiwara PI. Medical progress: management of tuberculosis in the United States. N Engl J Med. 2001;345:189-200.
31. Perlman D, El Helou P, Salomon N. Tuberculosis in patients with human immunodeficiency virus infection. Semin Respir Infect. 1999;14:344-352.
32. Cisneros JR, Murray KM. Corticosteroids in tuberculosis. Ann Pharmacother. 1996;30:1298-1303.
33. Dinarello CA. Anti-cytokine therapeutics and infections. Vaccine. 2003;21:S24-S34.
34. Kaplan G, Freedman VH. The role of cytokines in the immune response to tuberculosis. Res Immunol. 1996;147:565-572.
35. Flynn JL, Chan J. Immune evasion by Mycobacterium tuberculosis: living with the enemy. Curr Opin Immunol. 2003;15:450-455.
36. Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol. 2001;19:93-129.
37. Flynn JL, Goldstein MM, Triebold KJ, Sypek J, Wolf S, Bloom BR. Il-12 Increases resistance of Balb/C mice to Mycobacterium tuberculosis infection. J Immunol. 1995;155:2515-2524.
38. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM. Disseminated tuberculosis in interferon-gamma gene-disrupted mice. J Exp Med. 1993;178:2243-2247.
39. Scanga CA, Mohan VP, Tanaka K, Alland D, Flynn JL, Chan J. The inducible nitric oxide synthase locus confers protection against aerogenic challenge of both clinical and laboratory strains of Mycobacterium tuberculosis in mice. Infect Immun. 2001;69:7711-7717.
40. Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity. 1995;2:561-572.
41. Ottenhoff THM, Kumararatne D, Casanova JL. Novel human immunodeficiencies reveal the essential role of type-1 cytokines in immunity to intracellular bacteria. Immunol Today. 1998;19:491-494.
42. Aston C, Rom WN, Talbot AT, Reibman J. Early inhibition of mycobacterial growth by human alveolar macrophages is not due to nitric oxide. Am J Respir Crit Care Med. 1998;157:1943-1950.
43. Kisich KO, Higgins M, Diamond G, Heifets L. Tumor necrosis factor-alpha stimulates killing of Mycobacterium tuberculosis by human neutrophils. Infect Immun. 2002;70:4591-4599.
44. Saunders BM, Cooper AM. Restraining mycobacteria: role of granulomas in mycobacterial infections. Immunol Cell Biol. 2000;78:334-341.
45. Roach DR, Bean AGD, Demangel C, France MP, Briscoe H, Britton WJ. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol. 2002;168:4620-4627.
46. Johnson CM, Cooper AM, Frank AA, Orme IM. Adequate expression of protective immunity in the absence of granuloma formation in Mycobacterium tuberculosis-infected mice with a disruption in the intracellular adhesion molecule 1 gene. Infect Immun. 1998;66:1666-1670.
47. Rojas M, Olivier M, Gros P, Barrera LF, Garcia LF. TNF-alpha and IL-10 modulate the induction of apoptosis by virulent Mycobacterium tuberculosis in murine macrophages. J Immunol. 1999;162:6122-6131.
48. Bean AGD, Roach DR, Briscoe H, et al. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol. 1999;162:3504-3511.
49. Senaldi G, Yin S, Shaklee CL, Piguet PF, Mak TW, Ulich TR. Corynebacterium parvum- and Mycobacterium boris bacillus Calmette-Guerin-induced granuloma formation is inhibited in TNF receptor I (TNF-RI) knockout mice and by treatment with soluble TNF-RI. J Immunol. 1996;157:5022-5026.
50. Ehlers S, Kutsch S, Ehlers EM, Benini J, Pfeffer K. Lethal granuloma disintegration in mycobacteria-infected TNFRp55(-/-) mice is dependent on T cells and IL-12. J Immunol. 2000;165:483-492.
51. Bekker LG, Moreira AL, Bergtold A, Freeman S, Ryffel B, Kaplan G. Immunopathologic effects of tumor necrosis factor alpha in murine mycobacterial infection are dose dependent. Infect Immun. 2000;68:6954-6961.
52. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002;359:1187-1193.
53. Ruderman EM, Markenson J. Granulomatous infections and tumor necrosis factor antagonist therapies: update through June 2002. Arthritis Rheum. 2003;48(suppl 9):S241.
54. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor-alpha neutralizing agent. N Engl J Med. 2001;345:1098-1104.
55. Derk CT, DeHoratius RJ. Tuberculous tonsillitis in a patient receiving etanercept treatment. Ann Rheum Dis. 2003;62:372.
56. Wagner TE, Huseby ES, Huseby JS. Exacerbation of Mycobacterium tuberculosis enteritis masquerading as Crohn's disease after treatment with a tumor necrosis factor-alpha inhibitor. Am J Med. 2002;112:67-69.
57. US Food and Drug Administration MedWatch Program. Remicade (infliximab)-Black Box warning Oct, 23 2001 [letter] Centocor. Available at: http://www.fda.gov/medwatch/SAFETY/2001/remicadeTB_deardoc.pdf. Accessed August 2003.
58. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum. 2003;48(suppl 9):S240-S241.
59. Recommendation for the prevention and control of tuberculosis among foreign-born persons. MMWR Morb Mortal Wkly Rep. 1999;47(RR-16).
60. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003;48:2122-2127.
61. Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther. 2002;301:418-426.
62. Paimela L, Johansson-Stephansson EA, Leirisalo-Repo M. Depressed cutaneous cell-mediated immunity in early rheumatoid arthritis. Clin Exp Rheumatol. 1990;8:433-437.
63. Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis. 2003;3:148-155.
64. Menzies R, Vissandjee B. Effect of Bacille Calmette-Guerin vaccination on tuberculin reactivity. Am Rev Respir Dis. 1992;145:621-625.
65. Ewig S, Schlochtermeier M, Goke N, Niederman MS. Applying sputum as a diagnostic tool in pneumonia: limited yield, minimal impact on treatment decisions. Chest. 2002;121:1486-1492.
66. Takashima K, Tateda K, Matsumoto T, Iizawa Y, Nakao M, Yamaguchi K. Role of tumor necrosis factor alpha in pathogenesis of pneumococcal pneumonia in mice. Infect Immun. 1997;65:257-260.
67. Benton KA, VanCott JL, Briles DE. Role of tumor necrosis factor alpha in the host response of mice to bacteremia caused by pneumolysin-deficient Streptococcus pneumoniae. Infect Immun. 1998;66:839-842.
68. Heumann D, Barras C, Severin A, Glauser MP, Tomasz A. Gram-positive cell-walls stimulate synthesis of tumor necrosis factor-alpha and interleukin-6 by human monocytes. Infect Immun. 1994;62:2715-2721.
69. Houldsworth S, Andrew PW, Mitchell TJ. Pneumolysin stimulates production of tumor necrosis factor-alpha and interleukin-1-beta by human mononuclear phagocytes. Infect Immun. 1994;62:1501-1503.
70. Kerr AR, Irvine JJ, Search JJ, et al. Role of inflammatory mediators in resistance and susceptibility to pneumococcal infection. Infect Immun. 2002;70:1547-1557.
71. Dallaire F, Ouellet N, Bergeron Y, et al. Microbiological and inflammatory factors associated with the development of pneumococcal pneumonia. J Infect Dis. 2001;184:292-300.
72. Rijneveld AW, Florquin S, Hartung T, Speelman P, van der Poll T. Anti-tumor necrosis factor antibody impairs the therapeutic effect of ceftriaxone in murine pneumococcal pneumonia. J Infect Dis. 2003;188:282-285.
73. Mackay F, Loetscher H, Stueber D, Gehr G, Lesslauer W. Tumor necrosis factor-alpha induced cell-adhesion to human endothelial-cells is under dominant control of one TNF receptor type, TNF-R55. J Exp Med. 1993;177:1277-1286.
74. O'Brien DP, Briles DE, Szalai AJ, Tu AH, Sanz I, Nahm MH. Tumor necrosis factor-alpha receptor I is important for survival from Streptococcus pneumoniae infections. Infect Immun. 1999;67:595-601.
75. Rijneveld AW, Florquin S, Branger J, Speelman P, Van Deventer SJH, van der Poll T. TNF-alpha compensates for the impaired host defense of IL-1 type I receptor-deficient mice during pneumococcal pneumonia. J Immunol. 2001;167:5240-5246.
76. Karzai W, Melhhorn B, Eichacker PQ. Protection with antibody to tumor necrosis factor differs with similarly lethal Escherichia coli versus Staphylococcus aureus pneumonia in rats. Anesthesiology. 2003;99:81-99.
77. D'Souza M, Oettinger CW, Milton GV. Microspheres containing neutralizing antibodies to tumor necrosis factor-α and interleukin-1β protect rats from Staphylococcus aureus-induced peritonitis. J Interferon Cytokine Res. 2003;20:907-913.
78. Kurahashi K, Kajikawa O, Sawa T, et al. Pathogenesis of septic shock in Pseudomonas aeruginosa pneumonia. J Clin Invest. 1999;104:743-750.
79. Schumann J, Angermuller S, Bang R, Lohoff M, Tiegs G. Acute hepatotoxicity of Pseudomonas aeruginosa exotoxin A in mice depends on T cells and TNF. J Immunol. 1998;161:5745-5754.
80. Skerrett SJ, Martin TR, Chi EY, Peschon JJ, Mohler KM, Wilson CB. Role of the type 1 TNF receptor in lung inflammation after inhalation of endotoxin or Pseudomonas aeruginosa. Am J Physiol Lung Cell Mol Physiol. 1999;276:L715-L727.
81. Schultz MJ, Rijneveld AW, Florquin S, Edwards CK, Dinarello CA, van der Poll T. Role of interleukin-1 in the pulmonary immune response during Pseudomonas aeruginosa pneumonia. Am J Physiol Lung Cell Mol Physiol. 2002;282:L285-L290.
82. Laichalk LL, Kunkel SL, Strieter RM, Danforth JM, Bailie MB, Standiford TJ. Tumor necrosis factor mediates lung antibacterial host defense in murine Klebsiella pneumonia. Infect Immun. 1996;64:5211-5218.
83. Moreland LW, Russell AS, Paulus HE. Management of rheumatoid arthritis: the historical context. J Rheum. 2001;28:1431-1452.
84. Centers for Disease Control and Prevention. Current Centers for Disease Control adult vaccination recommendations. Available at: http://www.edc.gov/nip/ home-hcp. htm. Accessed September 2003.
85. Elkayam O, Paran D, Caspi D, et al. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Infect Dis. 2001;34:147-153.
86. Ellerin T, Rubin RH, Weinblatt ME. Infections and antitumor necrosis factor alpha therapy. Arthritis Rheum. 2003;48:3013-3022.
87. Wheat LJ, Kauffman CA. Histoplasmosis. Infect Dis Clin North Am. 2003;17:1-19.
88. Cano MV, Rodriguez E, Feikin D, et al. Histoplasmosis outbreak among college students: Acapulco, Mexico, 2001. Clin Infect Dis. 2001;33:1093.
89. Woods JP. Histoplasma capsulatum molecular genetics, pathogenesis, and responsiveness to its environment. Fungal Genet Biol. 2002;35:81-97.
90. Deepe GS. Immune response to early and late histoplasma capsulatum infections. Curr Opin Microbiol. 2000;3:359-362.
91. Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum. 2002;46:2565-2570.
92. True DG, Penmetcha M, Peckham SJ. Disseminated cryptococcal infection in rheumatoid arthritis treated with methotrexate and infliximab. J Rheum. 2002;29:1561-1563.
93. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol. 2001;96:722-729.
94. De Rosa FG, Shaz D, Campagna AC, Dellaripa PR, Khettry U, Craven DE. Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: a possible healthcare-associated case. Infect Control Hosp Epidemiol. 2003;24:477-482.
95. Tai TL, O'Rourke KP, McWeeney M, Burke CM, Sheehan K, Barry M. Pneumocystis carinil pneumonia following a second infusion of infliximab. Rheumatology. 2002;41:951-952.
96. Bergstrom L, Yocum DE, Villanueva I, Yung C. Coccidioidomycosis in patients treated with TNF-alpha antagonists is primary infection, not reactivation. Arthritis Rheum. 2003;47(suppl 9):S626.
97. Wing EJ, Gregory SH. Listeria monocytogenes: clinical and experimental update. J Infect Dis. 2002;185(suppl 1):S18-S24.
98. CDC Disease Information. Listeriosis. Available at: http://www.cdc.gov/ ncidod/dbmd/diseaseinfo/listeriosis. Accessed September 2003.
99. Rothe J, Lesslauer W, Lotscher H, et al. Mice lacking the tumor-necrosis-factor receptor-1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature. 1993;364:798-802.
100. Pfeffer K, Matsuyama T, Kundig TM, et al. Mice deficient for the 55Kd tumor necrosis factor receptor are resistant to endotoxic-shock, yet succumb to L. monocytogenes infection. Cell. 1993;73:457-467.
101. Slifman NR, Gershon SK, Lee JH, Edwards ET, Braun MM. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum. 2003;48:319-324.
102. Nuki G, Bresnihan B, Bear MB, McCabe D. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis. Arthritis Rheum. 2002;46:2838-2846.
103. Calabrese LH. Anakinra treatment of patients with rheumatoid arthritis. Ann Pharmacother. 2002;36:1204-1209.
104. Genovese MC, Cohen S, Moreland L, Bekker P. A randomized double-blind controlled study evaluating the safety and efficacy of etanercept vs etanercept plus anakinra in patients with rheumatoid arthritis. Ann Rheum Dis. 2003;EULAR Abstract OP0007.